FIGURE

Fig. 1

ID

ZDB-FIG-231102-16

Publication

Zisi et al., 2022 - Small Molecule-mediated Disruption of Ribosome Biogenesis Synergizes With FGFR Inhibitors to Suppress Glioma Cell Growth

Other Figures

All Figure Page

Back to All Figure Page

Fig. 1

RiBi is a relevant target for high-grade gliomas. (A) Differential expression (DE) analysis of RNAseq data between GBM (TCGA) and normal samples, with downregulated/green and upregulated/orange genes (log2FC > 0.5, padj < 0.05). (B) Reactome pathway enrichment analysis of DE genes from (A). z-score shows the tendency of genes within a term to be up/downregulated. (C) DE genes z-score-heatmap among GBM-normal or stages II to IV samples. (D) RiBi score and glioma grading association in TCGA cohort. (E) Kaplan–Mayer plot showing survival advantage of low versus moderate and high RiBi GBMLGG patients in TCGA. (F) BMH-21 dose–response (72 h) in normal human astrocytes (NHA) and glioma cell lines, with corresponding GI50 values (G) rDNA transcription in A172 and U18, quantified using an rRNA-promoter reporter assay. (H) Representative immunofluorescence images of nucleolar proteins FBL and UBF in glioma cells. Nuclei are counterstained with DAPI. Scale bar, 10 μm. (I) Indicated protein levels in glioma cells; beta-actin served as loading control (J–K) Click-it EdU-based cell-cycle analysis representative dot plots (J) and stacked barplot (K) of cell-cycle distribution into G1, S, and G2.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Neuro Oncol.